FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker(Erasmus MC Cancer Institute), Bas Groot Koerkamp, Andrea Wang‐Gillam(Washington University in St. Louis), Jason E. Faris(Royal Marsden NHS Foundation Trust), Thierry Conroy(Inserm), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Ian Chau(Royal Marsden NHS Foundation Trust), Florian Hohla(University of Salzburg), Ravi Shridhar(Florida Hospital Cancer Institute), Eran Sadot(Memorial Sloan Kettering Cancer Center), Sing Yu Moorcraft(National Health Service), Theodore S. Hong(Massachusetts General Hospital), Lysiane Marthey(Université Paris-Saclay), Jill Lacy(Smilow Cancer Hospital), Bassel F. El‐Rayes(University of Alabama at Birmingham), Peter J. Hosein(Markey Cancer Center), Berend R. Beumer(Erasmus University Rotterdam), Eric A. Mellon(Henry Ford Health System), Peter J. Allen(London School of Economics and Political Science), Casper H.J. van Eijck(Erasmus MC)
Cited by 914
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k